See more : Shanghai Shimao Co., Ltd. (600823.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Diamond Biofund Inc. (6901.TW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Diamond Biofund Inc., a leading company in the Asset Management industry within the Financial Services sector.
- Distil Plc (DIS.L) Income Statement Analysis – Financial Results
- Swedbank AB (publ) (SWDBF) Income Statement Analysis – Financial Results
- ASMedia Technology Inc. (5269.TW) Income Statement Analysis – Financial Results
- CFSB Bancorp, Inc. (CFSB) Income Statement Analysis – Financial Results
- Canadian Western Bank (CBWBF) Income Statement Analysis – Financial Results
Diamond Biofund Inc. (6901.TW)
Industry: Asset Management
Sector: Financial Services
About Diamond Biofund Inc.
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.24M | 1.02B | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 9.85M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.61M | 1.02B | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -339.04% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 137.59M | 102.43M | 404.64M | 64.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 152.38M | 137.59M | 102.43M | 404.64M | 64.46M |
| Other Expenses | 0.00 | 2.46M | -260.00K | -4.88M | -2.28M |
| Operating Expenses | 152.38M | 137.59M | 102.43M | 404.64M | 64.46M |
| Cost & Expenses | 162.23M | 137.59M | 102.43M | 404.64M | 64.46M |
| Interest Income | 16.24M | 861.00K | 120.00K | 1.97M | 0.00 |
| Interest Expense | 806.00K | 245.00K | 552.00K | 663.00K | 0.00 |
| Depreciation & Amortization | 9.85M | 11.47M | 11.86M | 12.02M | 10.56M |
| EBITDA | -2.59B | 892.83M | 2.97B | 6.13B | -53.90M |
| EBITDA Ratio | -115,503.48% | 87.91% | 0.00% | 0.00% | 0.00% |
| Operating Income | -162.23M | 881.37M | 2.96B | 6.10B | -367.78M |
| Operating Income Ratio | -7,229.59% | 86.78% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.42B | 3.08M | -692.00K | 17.81M | -2.98M |
| Income Before Tax | -2.58B | 881.12M | 2.96B | 6.11B | -370.76M |
| Income Before Tax Ratio | -115,143.63% | 86.76% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -412.00K | 83.34M | 108.98M | 25.19M | 110.00K |
| Net Income | -2.58B | 797.78M | 2.85B | 6.09B | -370.87M |
| Net Income Ratio | -115,125.27% | 78.55% | 0.00% | 0.00% | 0.00% |
| EPS | -3.32 | 1.07 | 3.01 | 6.19 | -0.55 |
| EPS Diluted | -3.32 | 1.03 | 2.98 | 6.10 | -0.55 |
| Weighted Avg Shares Out | 778.91M | 749.30M | 948.72M | 983.23M | 674.37M |
| Weighted Avg Shares Out (Dil) | 778.91M | 773.21M | 954.86M | 998.50M | 674.37M |
Source: https://incomestatements.info
Category: Stock Reports